The case for & against
Bull & Bear analysis
Bullish
Aquestive Therapeutics (NASDAQ: AQST) is a biopharmaceutical company specializing in innovative therapies for severe allergic reactions, aiming to transform the epinephrine market with its lead product, anafilm, a sublingual formulation of epinephrine. The company navigates a competitive landscape dominated by traditional auto-injectors and nasal sprays, leveraging its proprietary delivery technology to address unmet patient needs and improve access to life-saving medications in a growing market.
Bull says
- ↑Q1 2026 revenue rose 66% YoY to $14.4M, driven by license and manufacturing revenues.
- ↑Anifilm is the first sublingual epinephrine, targeting unmet patient preference for oral therapy.
- ↑Backed by $110M cash and a $150M debt facility, funding remaining FDA studies.
- ↑Sales force expanding 50% to ~75 reps focusing on top allergists and pediatricians.
- ↑Consumer surveys indicate strong demand for non-injectable epinephrine alternatives.
- ↑Strong growth metrics, positive dividend yield, and high liquidity support stock appeal.
Bear says
- ↓Potential advisory committee meeting could delay FDA approval of Anifilm.
- ↓Dominance of EpiPen and payer negotiations may hinder Anifilm reimbursement and access.
- ↓Q1 net loss of $8.1M highlights elevated pre-launch cash burn.
- ↓Negative earnings yield underscores lack of current profitability.
- ↓High short interest reflects market skepticism about AQST’s near-term outlook.
- ↓Weak profitability metrics and balance-sheet size may constrain valuation upside.
Investment themes with AQST
Pharmaceuticals↓ -0.08%
Drug development driving global healthcare solutions
LLY · JNJ · MRK
Most Shorted Stocks↑ +0.54%
Stocks with highest short interest
LITE · FSLY · SPHR
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-14-2026neutral
Transcript signals
Bull points
- For anisome-dibute epinephrine sublingual film, we have completed our type A face-to-face meeting with the FDA, completed a teleconference with the UK regulatory body known as MHRA, submitted our pediatric investigational plan to the European Medicines Agency, and submitted our human factors protocol for review by the FDA.
- Importantly, we were pleased to enter into a $150 million debt facility with Oaktree, a leading life sciences debt provider.
- we currently project that we will have greater than $150 million in cash at launch, and this is before considering ex-U.S. anafilm and U.S. Libervin outlicensing deals.
Bear points
- Coverage and reimbursement is a struggle for every company in life sciences.
- Her and her team are doing a lot of the great foundational work to make that happen, but I do want to set the expectation right for everyone listening today. It will take time, and it will be something that we have to build as we go through our launch.
- So that will be our approach on pushing for, hopefully, action sooner than the full six months.
Read full transcript analysis ›